HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.

AbstractThis article aims to provide an overview of efficacy and safety data on glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.
AuthorsMatthew P Gilbert, Richard E Pratley (Affiliation: Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont 05405, USA.)
JournalEuropean journal of internal medicine (Eur J Intern Med) Vol. 20 Suppl 2 Pg. S309-18 (Jul 2009) ISSN: 1879-0828 [Electronic] Netherlands
PMID19580950 (Publication Type: Journal Article, Review)
Chemical References
  • Incretins
Topics
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Humans
  • Incretins (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD